Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
Jhanelle E GrayMyung-Ju AhnGeoffrey R OxnardFrances A ShepherdFumio ImamuraYing ChengIsamu OkamotoByoung Chul ChoMeng-Chih LinYi-Long WuMargarita Majem TarruellaOliver GautschiMichael J BoyerKrishna C BulusuAleksandra A MarkovetsJ Carl BarrettRachel HodgeAstrid McKeownRyan J HartmaierJuliann ChmieleckiVassiliki A PapadimitrakopoulouSuresh R RamalingamPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Plasma EGFRm analysis as early as 3 weeks on-treatment has the potential to predict outcomes in EGFRm advanced NSCLC.